NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Forecast & News

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) issued its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. The biopharmaceutical company had revenue of $2.59 million for the quarter, compared to analyst estimates of $1.73 million. Corbus Pharmaceuticals had a negative net margin of 175.16% and a negative return on equity of 169.38%. View Corbus Pharmaceuticals' Earnings History.

Corbus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Corbus Pharmaceuticals.

6 brokers have issued 12-month price objectives for Corbus Pharmaceuticals' shares. Their forecasts range from $18.00 to $38.00. On average, they expect Corbus Pharmaceuticals' share price to reach $26.50 in the next year. This suggests a possible upside of 278.0% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.

Media coverage about CRBP stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Corbus Pharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Corbus Pharmaceuticals.

Some companies that are related to Corbus Pharmaceuticals include Tricida (TCDA), Arvinas (ARVN), Constellation Pharmaceuticals (CNST), Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Alder Biopharmaceuticals (ALDR), Esperion Therapeutics (ESPR), Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Theravance Biopharma (TBPH), BELLUS Health (BLUSF) and Nabriva Therapeutics (NBRV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Cronos Group (CRON), Western Digital (WDC) and Cara Therapeutics (CARA).

Corbus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include AE Wealth Management LLC (0.16%), Aries Wealth Management (0.04%) and IFP Advisors Inc (0.01%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.

CRBP stock was sold by a variety of institutional investors in the last quarter, including AE Wealth Management LLC and IFP Advisors Inc. View Insider Buying and Selling for Corbus Pharmaceuticals.

CRBP stock was bought by a variety of institutional investors in the last quarter, including Aries Wealth Management. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRBP stock can currently be purchased for approximately $7.01.

Corbus Pharmaceuticals has a market capitalization of $453.34 million and generates $4.82 million in revenue each year. The biopharmaceutical company earns $-55,670,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Corbus Pharmaceuticals employs 77 workers across the globe.View Additional Information About Corbus Pharmaceuticals.

The official website for Corbus Pharmaceuticals is http://www.corbuspharma.com/.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]